Hotline:400-820-3792

Inhibitors?ScreeningLibraries?Proteins

www.MedChemE

Everolimus-13C2,d4

Cat.No.:HY-10218S1

CASNo.:1661009-29-5

Synonyms:RAD001-13C,d;SDZ-RAD-13C,d

2424

分?式:C????C?H??D?NO??

分?量:964.23

作?靶点:Isotope-LabeledCompounds;Bacterial;Autophagy;FKBP;

mTOR;Apoptosis

作?通路:Others;Anti-infection;Autophagy;Apoptosis;CellCycle/DNA

Damage;Immunology/Inflammation;PI3K/Akt/mTOR

储存?式:Pleasestoretheproductundertherecommendedconditionsin

theCertificateofAnalysis.

BIOLOGICALACTIVITY

?物活性Everolimus-13C2,d4(RAD001-13C2,d4)是13C标记的Everolimus.Everolimus(RAD001)是?种雷帕霉素(

Rapamycin;HY-10219)的衍?物，也是?种有效的，选择性的和?服活性的mTOR1抑制剂。Everolimus与

FKBP-12结合可产?免疫抑制复合物。Everolimus抑制肿瘤细胞增殖并诱导细胞凋亡(apoptosis)和?噬(

autophagy)。Everolimus具有有效的免疫抑制和抗癌活性。

体外研究Stableheavyisotopesofhydrogen,carbon,andotherelementshavebeenincorporatedintodrugmolecules,

largelyastracersforquantitationduringthedrugdevelopmentprocess.Deuterationhasgainedattention

becauseofitspotentialtoaffectthepharmacokineticandmetabolicprofilesofdrugs.

REFERENCES

[1].RussakEM,etal.ImpactofDeuteriumS